Middle East and Africa Tulathromycin Market Size, Share & Trends Analysis Report By Animal Type (Cattle, Swine) and By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, The rest of MEA) Forecasts, 2026-2034

Last Updated: September 18, 2026 | Author: Dhanashri Chandgude | Format:

Middle East and Africa Tulathromycin Market Size

The Middle East tulathromycin market size was valued at USD 39.36 million in 2025 and is projected to grow from USD 41.01 million in 2026 to reach USD 56.90 million by 2034, growing at a CAGR of 4.18% during the forecast period 2026–2034.

Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves.

In addition, pet owners in the area are starting to pay greater attention to the health and welfare of their animals. They know the significance of giving their dogs the proper care to ensure a high quality of life. Veterinary clinics and other pet healthcare providers play a critical role in educating the public on the value of routine checkups, vaccines, and antibiotics when necessary.

Middle East and Africa Tulathromycin Market Size

Download a Free Sample To learn more about this report.

Animal Type Insights

The market is segmented into cattle and swine. Cattle dominated the market and is expected to register a CAGR of 3.9% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

Middle East and Africa Tulathromycin Market Size By Segments

Request Customizationto receive a tailored report.

Middle East and Africa Tulathromycin Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The market share held by MEA is the lowest. The Middle East's economies mostly rely on oil, and freshwater is in short supply. As a result, people in this area strive to avoid raising cattle and rely heavily on beef imports. On the other hand, most of the countries in the region are Muslim, which lowers the need for related goods and antibiotics like tulathromycin and pig rearing.

On the other hand, it has been discovered that several African nations produce beef and raise dairy cows. However, compared to other areas, adoption is much lower.

List of Key and Emerging Players in Middle East and Africa Tulathromycin Market

Zoetis

Zhejiang Genebest Pharmaceutical

Wisdom Pharmaceutical

Amicogen Biopharm

Hubei Honch Pharmaceutical

Livzon New North River Pharmaceutical

AVF Chemical Industrial

Jiangsu Lingyun Pharmaceutical

Key Industry Developments

June 2026

Zoetis expanded the availability of tulathromycin-based veterinary therapeutics across the Middle East and Africa through strengthened regional distribution partnerships, improving access to long-acting respiratory disease treatments for cattle and swine.

May 2026

Huvepharma expanded its veterinary pharmaceutical portfolio in the Middle East and Africa by introducing a new tulathromycin injectable formulation for the treatment of bovine and swine respiratory diseases.

September 2025

Vetoquinol enhanced its livestock health portfolio across the Middle East and Africa by expanding the distribution of long-acting macrolide antibiotics, including tulathromycin-based solutions, through regional veterinary partners.

June 2025

Norbrook expanded its injectable veterinary antibiotics portfolio by strengthening the supply of tulathromycin products for livestock producers across the Middle East and Africa, supporting improved respiratory disease management in cattle and swine.

Report Scope

Segmentation

By Animal Type 2

Cattle
Swine

Competitive Coverage Zoetis · Zhejiang Genebest Pharmaceutical · Wisdom Pharmaceutical · Amicogen Biopharm · Hubei Honch Pharmaceutical

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The market size is growing at a CAGR of 4.18% from 2026 to 2034.

Rising veterinary healthcare awareness is the key driver for the growth of this market.

The key players in this market are The Zoetis, Zhejiang Genebest Pharmaceutical, Wisdom Pharmaceutical, Amicogen Biopharm, Hubei Honch Pharmaceutical, Livzon New North River Pharmaceutical, AVF Chemical Industrial, Jiangsu Lingyun Pharmaceutical.

The key restraint in the market is Entry of generic tulathromycin.

About the Author

Dhanashri Chandgude

Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.